Soluble CD163 in Liver Diseases in Children
Fahmy, S., Rasmy, M., Ibrahim, A., Abdalkhalik, M. (2024). Soluble CD163 in Liver Diseases in Children. EKB Journal Management System, 5(4), 208-220. doi: 10.21608/ejmr.2023.221209.1415
Sameh Samir Fahmy; Mohamed Hamdy Rasmy; Asmaa Fathelbab Ibrahim; Mahmoud Mohamed Abdalkhalik. "Soluble CD163 in Liver Diseases in Children". EKB Journal Management System, 5, 4, 2024, 208-220. doi: 10.21608/ejmr.2023.221209.1415
Fahmy, S., Rasmy, M., Ibrahim, A., Abdalkhalik, M. (2024). 'Soluble CD163 in Liver Diseases in Children', EKB Journal Management System, 5(4), pp. 208-220. doi: 10.21608/ejmr.2023.221209.1415
Fahmy, S., Rasmy, M., Ibrahim, A., Abdalkhalik, M. Soluble CD163 in Liver Diseases in Children. EKB Journal Management System, 2024; 5(4): 208-220. doi: 10.21608/ejmr.2023.221209.1415

Soluble CD163 in Liver Diseases in Children

Egyptian Journal of Medical Research
Volume 5, Issue 4, October 2024, Page 208-220  XML PDF (451.1 K)
Document Type: Original Article
DOI: 10.21608/ejmr.2023.221209.1415
View on SCiNiTO View on SCiNiTO
Authors
Sameh Samir Fahmy1; Mohamed Hamdy Rasmy email 1; Asmaa Fathelbab Ibrahim2; Mahmoud Mohamed Abdalkhalik1
1Pediatrics department, Faculty of Medicine, Beni-Suef University
2Clinical and chemical pathology department, Faculty of medicine, Beni-Suef University, Egypt.
Abstract
Background: Activation of macrophages may be tracked in the blood through the biomarker soluble CD163 (sCD163). The purpose of this research is to determine the significance of soluble CD163 in the severity of liver disease in children. Methods: This study was a case control study performed on 128 children divided into cases with chronic hepatitis C (68 cases) and normal control group (60 cases). Patients fulfilling the criteria were evaluated with complete history, clinical examination, and laboratory investigations including ALT, AST and sCD 163 level. Results: This study showed that the serum sCD-163 had a significant role in prediction of the liver problem. The mean sCD-163 for patients with chronic hepatitis C was 17.7±7.2 and for controls was 9.8±1. Conclusions: The present study shows that the serum sCD-163 had a significant role in prediction of liver damage in patients with chronic hepatitis in children.
Keywords
sCD-163; chronic Hepatitis; Children
References
  1. Kazankov, K., Barrera, F., Møller, H.J., Bibby, B.M., Vilstrup, H., George, J. and Grønbæk, H., 2014. Soluble CD163, a macrophage activation marker, is independently associated with fibrosis in patients with chronic viral hepatitis B and C. Hepatology, 60(2), pp.521-530.
  2. Møller, H.J., Grønbæk, H., Schiødt, F.V., Holland-Fischer, P., Schilsky, M., Munoz, S., Hassanein, T., Lee, W.M. and US Acute Liver Failure Study Group, 2007. Soluble CD163 from activated macrophages predicts mortality in acute liver failure. Journal of hepatology, 47(5), pp.671-676.
  3. Andersen, C.B. and Moestrup, S.K., 2014. How calcium makes endocytic receptors attractive. Trends in biochemical sciences, 39(2), pp.82-90.
  4. Waidmann, O., Brunner, F., Herrmann, E., Zeuzem, S., Piiper, A. and Kronenberger, B., 2013. Macrophage activation is a prognostic parameter for variceal bleeding and overall survival in patients with liver cirrhosis. Journal of hepatology, 58(5), pp.956-961.
  5. Holland-Fischer, P., Grønbæk, H., Sandahl, T.D., Moestrup, S.K., Riggio, O., Ridola, L., Aagaard, N.K., Møller, H.J. and Vilstrup, H., 2011. Kupffer cells are activated in cirrhotic portal hypertension and not normalised by TIPS. Gut, 60(10), pp.1389-1393.
  6. Tacke, F. and Zimmermann, H.W., 2014. Macrophage heterogeneity in liver injury and fibrosis. Journal of hepatology, 60(5), pp.1090-1096.
  7. Jensen, M.K. and Balisteri, W.F., 2016. Viral Hepatitis. In: Nelson Textbbok of Pediatrics. Kliegman, R.M., Stanton, B.F., Schor, N.F., St Geme, J.W. and Behrman, R.E. (Ed.). 20th Pages 1942 – 1953.
  8. Triantafyllou, E., Woollard, K.J., McPhail, M.J., Antoniades, C.G. and Possamai, L.A., 2018. The role of monocytes and macrophages in acute and acute-on-chronic liver failure. Frontiers in immunology, 9, p.2948.
  9. Wang, J., Yu, Y., Yang, Y., Wu, S.S., Zhu, H.H., Liu, Y.N., Liu, W.X., Hu, Y., Wu, W., Xia, C.X. and Chen, Z., 2015. Expression of serum sCD163 in patients with liver diseases and inflammatory disorders. International Journal of Clinical and Experimental Pathology, 8(7), p.8419.
  10. Usman, A., Seerat, I., Rizvi, S.B., Sheraz, S. and Yousaf, H.A., 2022. Outcome of Treatment in Children With Chronic Viral Hepatitis C: A Single Centre Study. Cureus, 14(1).
  11. Roy, A., Samanta, T., Purkait, R., Mukherji, A. and Ganguly, S., 2013. Etiology, clinical spectrum and outcome of metabolic liver diseases in children. J Coll Physicians Surg Pak, 23(3), pp.194-8.
  12. Lodhi, M.A., Ayub, A., Saleem, M.Z., Hassan, S. and Rafique, S., 2020. ETIOLOGY AND CLINICAL PROFILE OF PEDIATRIC CHRONIC LIVER DISEASE. PAFMJ, 70(1), pp.38-42.
  13. Shivaraj, G., Prakash, D., Vinayak, H., Avinash, M., Sonal, V. and Shruthi, K., 2009. A review on laboratory liver function tests. Pan African Medical Journal, 3.
  14. Hyder, M.A., Hasan, M. and Mohieldein, A.H., 2013. Comparative levels of ALT, AST, ALP and GGT in liver associated diseases. European journal of experimental biology, 3(2), pp.280-284
  15. Cybulska, P., Ni, A. and Jimenez-Rivera, C., 2011. Viral hepatitis: retrospective review in a Canadian pediatric hospital. International Scholarly Research Notices, 2011.
  16. Schwarz, K.B., Cloonan, Y.K., Ling, S.C., Murray, K.F., Rodriguez-Baez, N., Schwarzenberg, S.J., Teckman, J., Ganova-Raeva, L., Rosenthal, P., Schwarz, K. and Murray, K., 2015. Children with chronic hepatitis B in the United States and Canada. The Journal of pediatrics, 167(6), pp.1287-1294.
  17. Isaac, A., Mo'nes, A.A., Wassfy, W.E.A. and El-Kilany, H.H., 2019. Soluble CD163 as a surrogate marker of fibrosis regression in chronic HCV patients receiving direct antiviral agents. Egyptian Journal of Hematology and Bone Marrow Transplantation, 6(7), pp.43-55.
  18. Mascia, C., Vita, S., Zuccalà, P., Marocco, R., Tieghi, T., Savinelli, S., Rossi, R., Iannetta, M., Pozzetto, I., Furlan, C. and Mengoni, F., 2017. Changes in inflammatory biomarkers in HCV-infected patients undergoing direct acting antiviral-containing regimens with or without interferon. PLoS One, 12(6), p.e0179400.
  19. Kazankov, K., Barrera, F., Møller, H.J., Bibby, B.M., Vilstrup, H., George, J. and Grønbæk, H., 2014. Soluble CD163, a macrophage activation marker, is independently associated with fibrosis in patients with chronic viral hepatitis B and C. Hepatology, 60(2), pp.521-530.
  20. Andersen, E.S., Rødgaard-Hansen, S., Moessner, B., Christensen, P.B., Møller, H.J. and Weis, N., 2014. Macrophage-related serum biomarkers soluble CD163 (sCD163) and soluble mannose receptor (sMR) to differentiate mild liver fibrosis from cirrhosis in patients with chronic hepatitis C: a pilot study. European journal of clinical microbiology & infectious diseases, 33(1), pp.117-122.
  21. Nielsen, M.C., Hvidbjerg Gantzel, R., Clària, J., Trebicka, J., Møller, H.J. and Grønbæk, H., 2020. Macrophage activation markers, CD163 and CD206, in acute-on-chronic liver failure. Cells, 9(5), p.1175.
 

Statistics
Article View: 271
PDF Download: 49